Clayman M D, Michaud L, Brentjens J, Andres G A, Kefalides N A, Neilson E G
J Clin Invest. 1986 Apr;77(4):1143-7. doi: 10.1172/JCI112414.
Using a monoclonal anti-tubular basement membrane antibody (alpha TBM-Ab) affinity column, we isolated from collagenase-solubilized human renal tissue (HSRTA) a predominantly 48,000-mol-wt moiety (H3M-1) which is selectively recognized by antisera from two patients with alpha TBM-Ab-associated interstitial nephritis (alpha TBM disease). Whereas both antisera had alpha TBM-Ab titers of 1:64-1:128 by immunofluorescence on tissue sections, their reactivity with H3M-1 in a solid-phase radioimmunoassay was demonstrable at dilutions up to 1:10,000. While these sera displayed some reactivity with pre-column HSRTA, this was markedly less than with H3M-1. HSRTA depleted of H3M-1 by passage over the alpha TBM-Ab affinity column was almost completely depleted of reactivity. Neither pooled normal human sera nor sera from patients with a variety of renal lesions not associated with alpha TBM-Ab (including interstitial nephritis and antiglomerular basement membrane disease) were reactive with H3M-1. Both patient antisera containing alpha TBM-Ab were also highly reactive with R3M-1, the 48,000-mol-wt rabbit glycoprotein antigen of experimental alpha TBM disease. Furthermore, a competitive inhibition radioimmunoassay revealed that alpha TBM-Ab from rodents with experimental alpha TBM disease could inhibit 45-98% of the R3M-1 binding reactivity of patient antisera and 85% of the H3M-1 binding reactivity of patient antisera, thus suggesting paratypic cross-reactivity. We conclude, therefore, that tubular basement membrane target epitopes and their paratypic recognition are highly conserved among mammals.
利用单克隆抗肾小管基底膜抗体(αTBM-Ab)亲和柱,我们从胶原酶溶解的人肾组织(HSRTA)中分离出一种主要为48,000道尔顿分子量的部分(H3M-1),它能被两名患有αTBM-Ab相关间质性肾炎(αTBM病)患者的抗血清选择性识别。虽然这两种抗血清在组织切片上通过免疫荧光检测的αTBM-Ab滴度为1:64 - 1:128,但它们在固相放射免疫测定中与H3M-1的反应性在高达1:10,000的稀释度下仍可检测到。虽然这些血清与柱前HSRTA有一些反应性,但明显低于与H3M-1的反应性。通过αTBM-Ab亲和柱去除H3M-1后的HSRTA几乎完全失去了反应性。正常人混合血清以及患有各种与αTBM-Ab无关的肾脏病变(包括间质性肾炎和抗肾小球基底膜病)患者的血清均与H3M-1无反应性。两种含有αTBM-Ab的患者抗血清也与实验性αTBM病的48,000道尔顿分子量兔糖蛋白抗原R3M-1有高度反应性。此外,竞争性抑制放射免疫测定显示,患有实验性αTBM病的啮齿动物的αTBM-Ab可抑制患者抗血清R3M-1结合反应性的45% - 98%以及患者抗血清H3M-1结合反应性的85%,从而提示了型间交叉反应性。因此,我们得出结论,肾小管基底膜靶抗原表位及其型间识别在哺乳动物中高度保守。